创新药概念局部活跃，消息面上，新修订的《中华人民共和国药品管理法实施条例》将于5月15日起施 行。国家药监局表示，这是条例实施二十多年来，首次全面修订。支持以临床价值为导向研究和创制新 药，提升仿制药质量和疗效。 中信证券研报称，2026年1月，阿里健康、京东健康两家头部医药电商平台相继正式发布面向医生的AI 医疗应用产品。看好头部医药电商平台凭借上游药企、下游C端用户资源，以及其母公司具备的AI基模 能力与产品能力，在ToD AI医疗应用领域脱颖而出，并率先跑通商业模式，实现AI医疗对主业的增收 赋能。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年1月28日 11:09，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，兴齐眼药领涨 1.42%，新和成上涨1.27%，片仔癀上涨0.27%；英科医疗领跌2.47%，华兰生物下跌2.22%，恩华药业下 跌2.22%。医疗创新ETF ...

Core Viewpoint - Alibaba Health's stock rose nearly 4%, reaching HKD 6.92 with a trading volume of HKD 506 million, following the launch of its AI medical application "Hydrogen Ion" with a new feature for "dynamic evidence positioning" [1] Group 1: Product Development - The "Hydrogen Ion" application now includes a feature that accurately identifies specific statements in original texts, verifying their timeliness, authority, and logical consistency [1] - This upgrade enhances the previous method of vague citations in AI responses to a precise identification of statements and their credibility [1] - The product has completed internal testing and is now available for download, targeting doctors in clinical and research fields [1] Group 2: Market Position and Outlook - CITIC Securities highlights that leading pharmaceutical e-commerce platforms, including Alibaba Health and JD Health, have launched AI medical applications aimed at doctors [1] - The report expresses optimism about these platforms leveraging resources from upstream pharmaceutical companies and downstream end-users, along with their parent companies' AI capabilities, to excel in the ToD AI medical application sector [1] - The expectation is that these companies will successfully establish a commercial model that enhances revenue through AI medical applications [1]

Core Viewpoint - Alibaba Health's stock rose nearly 4%, reaching HKD 6.92 with a trading volume of HKD 506 million, following the launch of its AI medical application "Hydrogen Ion" with a new feature for "dynamic evidence positioning" [1] Group 1: Product Development - The "Hydrogen Ion" application now offers precise citation of information, enhancing the reliability and timeliness of AI-generated responses, moving from vague references to specific statements [1] - The product has completed internal testing and is now available for download, targeting doctors in clinical and research fields [1] Group 2: Market Position and Outlook - CITIC Securities highlights that leading pharmaceutical e-commerce platforms like Alibaba Health and JD Health are launching AI medical applications for doctors [1] - The report expresses optimism about these platforms leveraging their resources from upstream pharmaceutical companies and downstream consumers, along with their parent companies' AI capabilities, to excel in the ToD AI medical application sector and successfully establish a commercial model [1]

Group 1 - Anta Sports plans to acquire 29.06% stake in PUMA SE for €1.5055 billion (approximately ¥12.278 billion) to enhance its global market position and brand influence [2] - Shandong Agricultural University Fertilizer Technology Co., Ltd. is set to be listed on the Beijing Stock Exchange on January 28, 2026, with an initial public offering of 16 million shares priced at ¥25.00 per share, raising a total of ¥400 million [2] Group 2 - DeepWay has completed a Pre-IPO financing round of ¥1.177 billion, marking the largest single financing in the autonomous driving new energy heavy truck sector [3] - Turing Quantum has secured several hundred million in Series B financing, continuing its trend of raising significant capital within six months [4] - AI medical innovation company Xu Zhi Shi has completed an A+ round of financing exceeding ¥50 million, with plans for a B round to be initiated after the Spring Festival [5] Group 3 - Elon Musk announced that SpaceX's Starship V3 will undergo its first flight test in six weeks, aiming to launch the next generation of Starlink V3 satellites [6] - Ying Shi Innovation is set to launch a dual-camera handheld gimbal camera, with product details leaked prior to the official announcement [7] - Apple has released a new version of AirTag, featuring a wider tracking range and louder speaker, priced at $29 for a single unit and $99 for a four-pack [10]

Group 1 - The company expects to achieve revenue between 3.6 billion to 3.9 billion yuan in 2025, with a significant narrowing of net profit loss for shareholders [1] - The company's performance is impacted by multiple factors including declining product prices due to intensified competition, extended customer payment cycles, and increased credit impairment losses [1] - Industry experts believe that despite facing temporary challenges, the company has positioned itself advantageously in high-potential sectors such as AI healthcare, consumer health management, and chronic disease prevention [1] Group 2 - The aging population in China is projected to reach 323 million people aged 60 and above by the end of 2025, creating a growing demand for chronic disease management and genetic testing [2] - The company is leveraging the aging trend and policy incentives to develop products for cognitive impairment and cardiovascular risk assessment, enhancing disease awareness and management among the elderly [2] - The company has implemented a personalized service model that integrates genetic, metabolic, and lifestyle data to provide tailored intervention plans [2] Group 3 - The company is advancing the integration of biotechnology and digitalization in AI healthcare, with the launch of the GeneT multi-modal model for genetic testing, currently in its pro version [3] - The company has introduced the SIRO high-throughput genetic testing AI solution, which has been deployed in over 40 top-tier hospitals across the country [3] - Although the pace of performance release has not yet aligned with strategic plans, the company's forward-looking layout and technological foundation in core sectors are expected to create long-term value [3]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the World Health Organization classifying it as a deadly zoonotic virus with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical Holdings Limited is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., is a high-tech enterprise established through a strategic investment with Carbon Cloud Intelligence, focusing on molecular diagnostics and offering comprehensive solutions in research, production, and technical services [1] Group 2: Technological Solutions - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, capable of supporting the entire process from rapid screening to precise tracing [1] - The intelligent fluorescent PCR rapid detection platform utilizes an AI primer design platform, integrating gene retrieval, automated primer design, and multi-dimensional performance evaluation, achieving rapid and accurate detection of high-risk pathogens like Nipah virus [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution covering both "wet experiments and dry analysis," enabling simultaneous detection and differentiation of Nipah virus and other co-existing pathogens [4] Group 3: Strategic Development - The rapid deployment of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant step in Huajian Medical's overall AI healthcare strategy [6] - The company is advancing its acquisition of Chuangye Huikang Technology Co., Ltd., aiming to establish a next-generation public health prevention paradigm that integrates AI early warning, rapid diagnosis, and ecological collaboration [6] - The product launch and strategic articulation demonstrate the company's commitment to the core paradigm of "intelligent capital driving continuous profit from knowledge," enhancing innovation efficiency and commercial value within its ecosystem through technology integration, data collaboration, and capital empowerment [6]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field through research, production, and technical services [1] Group 2: Technological Advancements - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening and precise tracing capability [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other coexisting pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technological capabilities of Huajian Medical in public health emergencies and is a significant validation of its strategic direction [4] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" and enhancing the innovative efficiency and commercial value of enterprises within its ecosystem [4]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the infection fatality rate reaching 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for infectious disease prevention and control [1] - The company’s subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field [1] Group 2: Technological Advancements - Carbon Hua has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening platform and a high-throughput sequencing and intelligent analysis platform [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other co-existing pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technical capabilities of Huajian Medical in public health emergencies and marks a significant step in advancing the company's AI medical strategy [3] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華檢醫療控股有限公司 ETHK Labs Inc. （於開曼群島註冊成立之有限公司） （前稱 IVD Medical Holding Limited ） （股份代號：1931） 自願性公告 關於子公司成功研發尼帕病毒檢測雙平台解決方案及 集 團AI醫療戰略升級的進展 一、背景與契機 近 日，印 度 西 孟 加 拉 邦 暴 發 尼 帕 病 毒 疫 情，世 界 衛 生 組 織 已 將 其 列 為 致 命 性 人 畜 共 患 病 毒，感 染 死 亡 率 可 達40%至75%，且 目 前 尚 無 特 效 療 法 或 疫 苗。此 類 新 發 突 發 傳 染 病 疫 情 凸 顯 全 球 公 共 衛 生 體 系 對 快 速、精 準 診 斷 與 預 警 能 力 的 迫 切 需 求。 作 為 長 期 深 耕 生 命 科 學 領 域 的 高 科 技 知 識 產 權 資 ...

Core Insights - Cathie Wood's ARK Invest is significantly increasing its investment in AI healthcare company Tempus AI, indicating strong confidence in the sector [2][9] - In two trading days, ARK Invest purchased approximately $4 million worth of Tempus AI stock, showcasing a bullish outlook on AI in healthcare [4][11] Company Overview - Tempus AI, founded in 2015, focuses on AI-enabled precision medicine, integrating clinical and molecular data to accelerate diagnostics, therapy selection, and drug development [4][11] - The company provides genomic sequencing and personalized diagnostic recommendations through its own laboratory, leveraging clinical histories [4][11] - Tempus AI licenses its extensive medical database and AI algorithms to pharmaceutical companies and research institutions to expedite drug development and optimize clinical trial designs [4][11] Financial Performance - Tempus AI reported approximately $1.27 billion in revenue for the previous year, reflecting a year-over-year growth of about 83% [5][12] Industry Trends - In the recent "Big Ideas 2026" report, it was highlighted that the healthcare industry is on the brink of transformation driven by AI and multi-omics, with expectations of a tenfold decrease in genomic sequencing costs and a fourfold reduction in drug development costs over the next five years [6][13] - The report also suggests a qualitative leap in human health span due to these advancements [6][13] Notable Initiatives - ChatGPTHealth is mentioned as an early example of AI application in healthcare, designed to enhance user health based on personal health data [7][13] - Cathie Wood has previously stated that healthcare is one of the most underestimated application areas for AI [8][13]